← Investor PortalInterested in the Company? Request more Information

MT574830

This health-tech company is pioneering AI-powered, smartphone-based diagnostics for eye health and neurological conditions. Its flagship productprovides portable, real-time assessments for vision disorders, concussions, and neurodegenerative diseases, making healthcare more accessible, affordable, and efficient.
‍
With a $198B market opportunity, a rapidly expanding telemedicine industry, and growing demand for remote diagnostics, the company is positioned to disrupt traditional eye and neurological exams. Its proprietary AI technology, patent-protected innovations, and early hospital partnerships give it a strong competitive edge in a high-growth digital health sector.
‍
Now raising $3M to advance clinical trials, regulatory approvals, and market expansion, this is an opportunity to invest in a first-mover company transforming how vision and neurological health are diagnosed worldwide.

Overview

  • Industry: Digital Health, Telemedicine, AI-Powered Diagnostics
  • Founded: 2017
  • Location: Canada
  • Core Focus: Developing smartphone-based AI diagnostics for eye health and neurological conditions, with a strong focus on remote care and concussion assessment.
  • Technology: AI-driven vision and neurological assessments via EyeMirage, a portable, smartphone-based diagnostic tool.
  • Development Stage: Minimum Viable Product (MVP) complete, preparing for clinical trials.
  • Intellectual Property: 2 patent families, 13 active patents, proprietary AI-driven diagnostic models.
  • Go-To-Market Strategy: Partnerships with hospitals, sports organizations, telemedicine providers, and consumer retail.
  • Funding Required: $3M for product development, clinical trials, regulatory approvals, and market expansion.

Problem & Solution

  • The Problem

    → Limited access to eye and neurological diagnostics    —patients in remote areas or with mobility issues struggle to receive timely assessments.

    → High cost and long wait times for in-clinic assessments, leading to delays in diagnosis and treatment.

    → Lack of portable, real-time concussion assessments    , putting athletes at risk of further injury.

    → Need for continuous monitoring of chronic eye and neurological conditions.
  • The Solution

    → Product    : A smartphone-based, AI-powered diagnostic tool that provides affordable, real-time assessments for eye health, concussions, and neurological conditions.

    → Portable and accessible, enabling remote diagnosis for underserved populations.

    → Cost-effective, reducing expenses for patients and healthcare providers.

    → Instant concussion assessments, ensuring immediate decision-making in sports and emergency settings.

Market Potential

  • Target Markets: Global eye examination and concussion diagnostics markets.
  • Market Size:

    ‍TAM: $198B
    ‍SAM: $4.5B
    ‍SOM: $460M
  • Growth Rate:

    ‍Eye Examination Market: 25% CAGR (2022–2029)
    ‍Concussion Market: 3.6% CAGR
  • Key Trends:

    → Expansion of AI-powered diagnostics in healthcare
    → Rising demand for telemedicine and remote assessments
    → Growing sports safety regulations requiring concussion screening
    → Increasing demand for affordable, portable diagnostic tools

Product & Technology

  • Core Offering:
    ‍
    →     AI-powered, smartphone-based diagnostic tool for vision and neurological assessments.
    → Detects concussions, glaucoma, and neurodegenerative disorders through image analysis and machine learning.
  • Technology Stack:

    ‍AI-driven image processing and machine learning models for vision and neurological assessments.
    ‍Cloud-based data storage with secure, HIPAA-compliant encryption.
    ‍Mobile-first platform, compatible with iOS and Android devices.
  • Development Stage: MVP completed, preparing for clinical trials and regulatory approval.
  • Intellectual Property:
    → 13 active patents covering mobile eye exams and concussion diagnostics.
    → Proprietary AI models for visual and neurological pattern recognition.
  • Future Features:

    → Optical Coherence Tomography (OCT) for retinal imaging.
    ‍→ ‍Funduscopy for retinal and optic nerve analysis.
    → Refraction exams for remote eyeglass prescriptions.

Business Model & Revenue Strategy

  • Revenue Model:

    → Device Sales: One-time purchase of EyeMirage diagnostic devices.
    → Subscription-Based AI Diagnostics: Monthly or annual fee for advanced AI-powered analysis.
    → Premium Telehealth Consultations: On-demand specialist access via the platform.
    → Healthcare Data Insights: Anonymized data for medical research and analytics (fully compliant with privacy laws).
  • Pricing Strategy:

    → Device Price: Competitively priced for consumer, clinical, and sports markets.
    → Subscription Model: Multiple tiers based on diagnostic complexity and provider integration.
  • Sales Channels:

    → Direct-to-consumer via online marketplaces (Amazon, Neuroptek website).
    → B2B sales through hospitals, clinics, and telemedicine providers.
    → Retail partnerships with pharmacies and medical suppliers.
    → Sports industry partnerships for concussion monitoring in leagues and athletic programs.
  • Customer Acquisition & Retention:

    → Digital marketing campaigns targeting consumers and healthcare providers.
    → Partnerships with hospitals and telemedicine providers for early adoption.
    → Subscription-based model ensures long-term customer retention.

Competitive Edge

  • Only smartphone-based AI tool combining eye and neurological diagnostics.
  • Portable and affordable—competitors require expensive, in-clinic equipment.
  • Instant results, enabling early detection and faster intervention.
  • Integrated concussion assessment, a major unmet need in sports and emergency care.
  • Regulatory and patent barriers make replication by competitors challenging.

Traction & Milestones

  • Early hospital and research partnerships secured for clinical validation.
  • Prototype completed and preparing for clinical trials.
  • Winner of People’s Choice Award at a neuro-tech pitch competition.
  • Recognized in industry publications for innovation in AI-driven diagnostics.

Financials

  • Current Burn Rate: $30K/month (pre-marketing), $75K/month (post-marketing ramp-up).
  • Runway: 12–18 months (pre-funding).
  • Total Funding to Date: $2.5M+ (grants, bootstrapping, pre-seed fundraising).
  • Projected Revenue:

    2026: $11.3M
    ‍2027: $23.1M
    ‍2028: $45.6M
    ‍2029: $72.1M
    ‍2030: $105.2M

Team

  • CEO & Founder – Neurologist and neuro-ophthalmologist with expertise in AI-driven eye care solutions.
  • CFO – Neurologist specializing in concussion care and financial strategy.
  • Chief Medical Officer – Medical doctor & neuroscientist, overseeing clinical validation and software accuracy.
  • Regulatory Advisor – Expert in FDA & Health Canada compliance, clinical trials.
  • Biomedical Engineering Advisor – Specialist in signal processing and neurophysiological measurements.

Risks & Mitigation

  • Regulatory Approval Delays – Working with experienced compliance consultants for FDA/Health Canada submissions.
  • Market Adoption Hesitation – Partnering with leading hospitals, sports organizations, and key opinion leaders.
  • Financial Risks – Diversified revenue model (device sales + subscriptions + research data partnerships).

Funding Requirements

  • Funding Required: $3M
  • $600K – Product development
  • $300K – Clinical trials & regulatory approvals
  • $1.25M – Marketing & sales expansion
  • $650K – Hiring key personnel
  • $200K – R&D and operational contingencies

Exit Strategy

  • IPO: Targeting 2030 for public market entry and global expansion.
  • Acquisition: Medical device, telemedicine, and digital health companies seeking AI-powered diagnostics.
  • Strategic Partnerships: Expanding co-development opportunities with healthcare and technology leaders.

Why Invest?

  • First-mover advantage in AI-powered eye and neurological diagnostics.
  • $198B market opportunity with high-growth telemedicine adoption.
  • Strong IP portfolio protecting innovative technology.
  • Early traction and strategic partnerships already secured.
  • Clear exit strategy with IPO or acquisition potential.

Pitch Deck

View the deck through the link below—while some unique identifiers have been removed, it still offers a great overview. For access to detailed investor materials, please reach out to us, as full decks are only shared upon request to maintain confidentiality and exclusivity.

View Pitch Deck

Interested in the startup?

Let us know, if you'd like to request more information about the company, or if you'd like to hear a great pitch first.

Investor Interest Form